Oak Ridge Investments LLC Sells 1,208 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Oak Ridge Investments LLC reduced its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 39,010 shares of the medical equipment provider’s stock after selling 1,208 shares during the period. Oak Ridge Investments LLC owned about 0.06% of Lantheus worth $3,490,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Janus Henderson Group PLC raised its stake in Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after acquiring an additional 257,022 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after purchasing an additional 796,000 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Reinhart Partners LLC. lifted its holdings in Lantheus by 9.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock valued at $122,280,000 after purchasing an additional 123,282 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Lantheus by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after buying an additional 19,071 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on LNTH. JMP Securities reissued a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial reissued a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group assumed coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $91.47 on Friday. The stock has a market cap of $6.36 billion, a price-to-earnings ratio of 15.22 and a beta of 0.46. The company has a 50 day moving average of $89.72 and a 200-day moving average of $99.99. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 2.10% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.